Singlera Genomics signed a research and distribution agreement with EU‑based Pure Medical to commercialize its methylation‑based cell‑free DNA assays (mTitan and mGuard) across selected European markets. The deal covers distribution, research collaborations with hospitals and universities, and aims to expand access to low‑cost early cancer detection and monitoring tools. Singlera’s COO Qiang Liu framed the agreement as a strategic step in the company’s European expansion.